Marcus and Feldman's Osteoporosis

Marcus and Feldman's Osteoporosis, Fifth Edition, is the most comprehensive, authoritative reference on this disease. Led by a new editorial team, this fifth edition offers critical information on reproductive and hormonal risk factors, new therapeutics, ethnicity, nutrition, therapeutics, management and economics, comprising a tremendous wealth of knowledge in a single source not found elsewhere. Written by renowned experts in the field, this two-volume reference is a must-have for biomedical researchers, research clinicians, fellows, academic and medical libraries, and any company involved in osteoporosis drug research and development.

• Summarizes the latest research in bone biology and translational applications in a range of new therapeutic agents, including essential updates on therapeutic uses of calcium, vitamin D, SERMS, bisphosphonates, parathyroid hormone, and new therapeutic agents
• Recognizes the critical importance of new signaling pathways for bone health, including Wnt, OPG and RANK, of interest to both researchers who study bone biology and clinicians who treat osteoporosis
• Offers new insights into osteoporosis associated with menopause, pre-menopause, chronic kidney disease, diabetes, HIV and other immune disorders

Table of Contents

Volume 1.
Part I. Introduction   
1. The Nature of Osteoporosis  
2. The Bone Organ System: Form and Function
Part II. Developmental, Cellular and Molecular Biology of Bone
3. Development of the Skeleton
4. The Skeletal Stem Cell
5. Osteoclast Biology
6. Osteoblast Biology: Developmental Origin and Interactive Nature of Osteoblasts
7. Osteocytes
8. The Regulatory Role of Matrix Proteins in Mineralization of Bone
Part III. Skeletal Hormones and Regulatory Factors
9. Parathyroid Hormone and Parathyroid Hormone-Related Protein
10. Phosphatonins 
11. Skeletal Growth Factors
12. WNT Signaling in Skeletal Homeostasis and Diseases
Part IV. Biomechanics and Mechanobiology
13. The Mechanical Behavior of Bone
14. Cellular and Molecular Mechanotransduction in Bone
15. Adaptation of Skeletal Structure to Mechanical Loading
16. Biomechanics of Hip and Vertebral Fractures
Part V. Epidemiology of Osteoporosis
17. Epidemiologic Methods in Studies of Osteoporosis
18. Genetics of Osteoporosis
19. Race, Ethnicity, and Osteoporosis 
20. Geographic Variability in the Incidence of Hip and Vertebral Fractures
21. Nutrition and Osteoporosis
22. Physical Activity, Exercise and Skeletal Health
23. Reproductive and Hormonal Factors and the Risk for Osteoporosis
24. Clinical and Epidemiological Studies: Skeletal Changes across Menopause
25. Osteoporosis in Men: What is Similar and What is Different?
26. Falls as Risk Factors for Fracture
27. Impact of Physical Characteristics and Lifestyle Factors on Bone Density and Fractures
28. Imminent Fracture Risk and Disability Post Fracture
29. Economics of Osteopososis
Part VI. General Pathophysiology of Osteoporosis
30. Skeletal Heterogeneity and the Purposes of Bone Remodeling
31. On the Evolution and Contemporary Roles of Bone Remodeling
32. Estrogen Deficiency and the Pathogenesis of Osteoporosis
33. Cytokines and the Pathogenesis of Osteoporosis
34. Bone and Fat
35. Bone, Muscle, and Sarcopenia
36. Bone Mineral Acquisition in Utero and During Infancy and Childhood
37. Osteoporosis in Childhood and Adolescence
38. Osteoporosis in Premenopausal Women, Pregnancy, and Lactation
39. Bone and the Microbiome

Volume 2.
Part VII. Impact of Comorbidity and Medications on Skeletal Health
40. Immobilization Osteoporosis
41. Osteoporosis in Neurological Disorders: Parkinson’s Disease, Stroke, and Multiple Sclerosis--July 28, 2019
42. Effects on the Skeleton from Medications Used to Treat Non-skeletal Disorders
43. Osteoporosis associated with gastrointestinal disorders; celiac and inflammatory bowel diseases
44. Osteoporosis Associated with Eating Disorders
45. Glucocorticoid-Induced Osteoporosis and Cushing's Syndrome
46. Thyroid Hormone, Thyroid Medication, and the Skeleton
47. The Skeletal Actions of Parathyroid Hormone in Primary Hyperparathyroidism
48. Osteogenesis Imperfecta and Other Defects of Bone Development as Occasional Causes of Adult Osteoporosis
49. Human Immunodeficiency Virus and Osteoporosis 
50. Diabetes, Diabetic Medications, and Risk of Fracture
51. Skeletal Health after Bariatric Surgery
52. Osteoporosis in Organ Transplant Patients
53. Osteoporosis Associated with Rheumatologic Disorders
54. Osteoporosis Associated with Chronic Kidney Disease
55. Relationship Between Periodontal Disease, Tooth Loss and Osteoporosis
56. Impact of Breast Cancer and its treatment on Bone Loss and Fracture Risk – Pathophysiology and Management
57. Management of Bone Health in Men with Prostate Cancer
58. Impact of MGUS and Myeloma on Skeletal Health
59. Renal Stone Disease, Hypercalciuria and Osteoporosis: Use of Thiazides and Alkali for Osteoporosis
60. Sleep Disorders and Osteoporosis
Part VIII. Diagnosis and Evaluation
61. Evaluation of the Osteoporosis Patient
62. Who Should be Screened for Osteoporosis?
63. Vertebral Fracture Identification
64. Noninvasive Imaging Techniques and Fracture Risk Assessment
65. Biochemical Markers of Bone Turnover in Osteoporosis
66. A Comparison of Fracture Risk Assessment Tools
Part IX. Patient Management
67. Orthopedic Aspects of Osteoporosis
68. Fall Prevention Interventions
69. Exercise and Other Physical Therapy Interventions in the Management of Osteoporosis
70. Calcium and Vitamin D in the Management of Osteoporosis
71. Nutrients Beyond Calcium and Vitamin D to Treat Osteoporosis
72. Condition Still Critical: Compliance and Persistence with Osteoporosis Medications
Part X. Pharmacotherapeutics
73. Estrogen and Estrogen Analogs for Prevention and Treatment of Osteoporosis
74. Bisphosphonates  Pharmacology and Use in the Treatment of Osteoporosis
75. Denosumab for the Treatment of Osteoporosis
76. Teriparatide and Abaloparatide Treatment for Osteoporosis
77. Calcitonin in Osteoporosis
78. Androgens
79. Long-term Bisphosphonate Treatment: Continuation and Interruption
80. Romosozumab in the Treatment of Postmenopausal Osteoporosis
81. Lessons from Bone Histomorphometry on the Mechanisms of Action of Osteoporosis Drugs
Part XI. New Directions
82. Longterm Treatment Strategies and Goal Directed Therapy

OUR VISITORS OPINIONS